ZAMONAVIY ANTIDEPRISSANTLAR TA`SIR MEHANIZMLARI VA FARMAKOLOGIK SAMARASI.
Keywords:
Kalit so`zlar: Depressiya, Affektiv buzilishlar, Serotonin, Dofamin, Glutamat, GABA, Antidepressantlar, Ketamin, SSRI, NMDA retseptorlariAbstract
Annotatsiya: Ushbu ilmiy maqolada xozirgi kunda dolzarb bo`lgan
tehnologiyalarning jadallashiuvi va insonlarda asab tizimiga kelayotgan yuklamalar
ko`pligi oqibatida kelib chiqayotgan global muammolardan biri depressiv xolatlarda
zamonaviy antidepressant dori vositalaridan to`gri foydalanishga qaratilgan.
Depresisya holatlarida organizmda bo`ladigan o`zgarishlar, unda kechadigan
jarayonlar ilmiy dalillar asosida ko`rib chiqiladi,Antideprissantlarning turlari va
bemorning xolatiga qarab bu vositalarni qo`llash bemorni ijtimoiy xayotga, aqliy va
jismoniy xolatini yahshilashga bo`lgan samaralari yoritib
boriladi.Antideprissantlarning farmakologik ta`sir mehanizmi va klinik samaradorligi
yoritib beriladi.
References
Foydalanilgan adabiyotlar
1.Nemeroff CB. Recent advances in the neurobiology of depression.
Psychopharmacol Bull. 2002; 36(Suppl 2): 6-23.
2.Li Z, Ruan M, Chen J, Fang Y. Major depressive disorder: advances in
neuroscience research and translational applications. Neurosci Bull. 2021; 37(6): 863-
880.
3.De-Miguel FF, Trueta C. Synaptic and extrasynaptic secretion of serotonin.
Cell Mol Neurobiol. 2005; 25(2): 297-312.
4.Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative
(I&ND) hypothesis of depression: leads for future research and new drug developments
in depression. Metab Brain Dis. 2009; 24(1): 27-53.
5.Deakin JF, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol.
1991; 5(4): 305-315.
6.Xue Y, Liang H, Yang R, Deng K, Tang M, Zhang M. The role of pro- and
mature neurotrophins in the depression. Behav Brain Res. 2021; 404:113162.
7.Babaev O, Cruces Solis H, Arban R. Dopamine modulating agents alter
individual subdomains of motivation-related behavior assessed by touchscreen
procedures. Neuropharmacology. 2022:109056.
8.Salamone JD, Ecevitoglu A, Carratala-Ros C, et al. Complexities and
paradoxes in understanding the role of dopamine in incentive motivation and
instrumental action: Exertion of effort vs. anhedonia. Brain Res Bull. 2022; 182: 57-
66.
9.Mercuri NB, Federici M, Rizzo FR, et al. Long-term depression of striatal DA
release induced by mGluRs via sustained hyperactivity of local cholinergic
interneurons. Front Cell Neurosci. 2021; 15:798464.
1032.Duval F, Mokrani MC, Erb A, Gonzalez Lopera F, Danila V, Tomsa M.
Neuroendocrine assessment of dopaminergic function during antidepressant treatment
in major depressed patients. Brain Sci. 2021; 11(4):425.
11.Zaghmi A, Perez-Mato M, Dopico-Lopez A, Candamo-Lourido M, Campos
F, Gauthier MA. New perspectives for developing therapeutic bioconjugates of
metabolite-depleting enzymes: lessons learned combating glutamate excitotoxicity.
Biomacromolecules. 2022;23:1864-1872.
12.Li MX, Li Q, Sun XJ, et al. Increased Homer1-mGluR5 mediates chronic
stress-induced depressive-like behaviors and glutamatergic dysregulation via
activation of PERK-eIF2alpha. Prog Neuropsychopharmacol Biol Psychiatry. 2019;
95:109682.
13.Chen Y, Shen M, Liu X, Xu J, Wang C. The regulation of glutamate
transporter 1 in the rapid antidepressant-like effect of ketamine in mice. Front Behav
Neurosci. 2022; 16:789524.
14.Tomasetti C, Montemitro C, Fiengo ALC, et al. Novel pathways in the
treatment of major depression: focus on the glutamatergic system. Curr Pharm Des.
2019; 25(4): 381-387.
15.Hashimoto K. The role of glutamate on the action of antidepressants. Prog
Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1558-1568.
16.Gray AL, Hyde TM, Deep-Soboslay A, Kleinman JE, Sodhi MS. Sex
differences in glutamate receptor gene expression in major depression and suicide. Mol
Psychiatry. 2015; 20(9): 1057-1068.
18.Chandley MJ, Szebeni A, Szebeni K, et al. Elevated gene expression of
glutamate receptors in noradrenergic neurons from the locus coeruleus in major
depression. Int J Neuropsychopharmacol. 2014; 17(10): 1569-1578.
19.Musazzi L, Treccani G, Mallei A, Popoli M. The action of antidepressants on
the glutamate system: regulation of glutamate release and glutamate receptors. Biol
Psychiatry. 2013; 73(12): 1180-1188.
20.Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA, Jr.
Glutamatergic neurotransmission: pathway to developing novel rapid-acting
antidepressant treatments. Int J Neuropsychopharmacol. 2019; 22(2): 119-135.
21.Beurel E, Grieco SF, Amadei C, Downey K, Jope RS. Ketamine-induced
inhibition of glycogen synthase kinase-3 contributes to the augmentation of alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.
Bipolar Disord. 2016; 18(6): 473-480.
22.Gould TD, O'Donnell KC, Dow ER, Du J, Chen G, Manji HK. Involvement
of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail
suspension test and forced swim test. Neuropharmacology. 2008; 54(3): 577-587.
23.Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression:
GABA and glutamate neurotransmitter deficits and reversal by novel treatments.
Neuron. 2019; 102(1): 75-90.
24.Zhang X, Liu Y, Hong X, et al. NG2 glia-derived GABA release tunes
inhibitory synapses and contributes to stress-induced anxiety. Nat Commun. 2021;
12(1): 5740.
25.Lowes DC, Chamberlin LA, Kretsge LN, et al. Ventral tegmental area GABA
neurons mediate stress-induced blunted reward-seeking in mice. Nat Commun. 2021;
12(1): 3539.
26.Farrell MR, Esteban JSD, Faget L, Floresco SB, Hnasko TS, Mahler SV.
Ventral pallidum GABA neurons mediate motivation underlying risky choice. J
Neurosci. 2021; 41(20): 4500-4513.
27.Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as
antidepressants: does GABA play a role in depression? Biol Psychiatry. 1995; 38(9):
578-591.
28.Ghosal S, Hare B, Duman RS. Prefrontal cortex GABAergic deficits and
circuit dysfunction in the pathophysiology and treatment of chronic stress and
depression. Curr Opin Behav Sci. 2017; 14: 1-8.
29.Fee C, Banasr M, Sibille E. Somatostatin-positive gamma-aminobutyric acid
interneuron deficits in depression: cortical microcircuit and therapeutic perspectives.
Biol Psychiatry. 2017; 82(8): 549-559.
30.Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ.
GABAergic neurons immunoreactive for calcium binding proteins are reduced in the
prefrontal cortex in major depression. Neuropsychopharmacology. 2007; 32(2): 471-
482.
31.Schur RR, Draisma LW, Wijnen JP, et al. Brain GABA levels across
psychiatric disorders: a systematic literature review and meta-analysis of (1) H-MRS
studies. Hum Brain Mapp. 2016; 37(9): 3337-3352.
32.Mann JJ, Oquendo MA, Watson KT, et al. Anxiety in major depression and
cerebrospinal fluid free gamma-aminobutyric acid. Depress Anxiety. 2014; 31(10):
814-821.
33.Guilloux JP, Douillard-Guilloux G, Kota R, et al. Molecular evidence for
BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major
depression. Mol Psychiatry. 2012; 17(11): 1130-1142.
34.Karolewicz B, Maciag D, O'Dwyer G, Stockmeier CA, Feyissa AM,
Rajkowska G. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal
cortex in major depression. Int J Neuropsychopharmacol. 2010; 13(4): 411-420.
